FHTX Earnings
Latest Revenue83.5M
Latest Net Income58.1M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q3 2026 | $0.81 | 83.5M | 58.1M | +924.7% | +424.0% |
| Q2 2026 | -$0.10 | 16.1M | -7191000 | +112.7% | +64.3% |
| Q1 2026 | -$0.29 | 3.3M | -19875000 | -45.1% | +3.3% |
| Q4 2025 | -$0.34 | 9.2M | -21664000 | +223.8% | -9.7% |
| Q3 2025 | -$0.25 | 8.2M | -15849000 | +4.4% | +19.4% |
| Q2 2025 | -$0.28 | 7.6M | -17936000 | +9.7% | +37.8% |
| Q1 2025 | -$0.30 | 6.0M | -18834000 | +17.9% | +49.2% |
| Q4 2024 | -$0.31 | 2.9M | -19503000 | -50.5% | +45.6% |
| Q3 2024 | -$0.31 | 7.8M | -19122000 | — | — |
| Q2 2024 | -$0.45 | 6.9M | -22979000 | — | — |
| Q1 2024 | -$0.59 | 5.0M | -25016000 | — | — |
| Q4 2023 | -$0.57 | 5.8M | -24106000 | — | — |
Foghorn Therapeutics (FHTX) — Earnings